Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events

Item8.01 Other Events

On January8, 2017, Esperion Therapeutics,Inc. issued a press
release titled, Esperion Announces Initiation of Three Pivotal
Phase 3 Studies for Bempedoic Acid (the Phase 3 Press Release). A
copy of the Phase 3 Press Release is filed herewith as
Exhibit99.1 and is incorporated herein by reference.

On January9, 2017, Esperion Therapeutics,Inc. issued a press
release titled, Esperion Announces Initiation of Global
Cardiovascular Outcomes Trial for Bempedoic Acid (the CVOT Press
Release). A copy of the CVOT Press Release is filed herewith as
Exhibit99.2 and is incorporated herein by reference.

Item9.01 Financial Statements and Exhibits.

(d)Exhibits

* * *

About Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information

Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session up +0.06 at 13.84 with 888,303 shares trading hands.